Regeneron Showcases Updated on BLA for Linvoseltamab to Treat R/R Multiple Myeloma (MM)
Shots:
- The US FDA has issued a CRL related to the BLA for Linvoseltamab for the treatment of 3L+ r/r MM. Regeneron presented results and during its Q2’24 earnings call.
- As per Regeneron, pre-approval inspection at a third-party fill/finish manufacturer has been completely and awaiting FDA re-inspection in next few months and expecting to receive resolution and approval.
- Linvoseltamab is a bispecific antibody that promotes the interaction of BCMA x CD-3 expressing T-cell on MM cells. Regeneron's Linvoseltamab is under regulatory review by the EMA for the same indication
Ref: Regeneron | Image: Regeneron
Related News:- Regeneron Showcases Updated P-I/II (LINKER-MM1) Study Data of Linvoseltamab for Treating R/R Multiple Myeloma at EHA 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
